Reblozyl (luspatercept) Erythroid Maturation Agent

For your adult patients with
MDS- or β-thalassemia–associated anemia

With Reblozyl—the first and only erythroid maturation agent—you can reduce or even eliminate patients’ red blood cell (RBC) transfusion dependence.^1-3

Reblozyl is indicated for the treatment of adult patients with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.

Reblozyl is indicated for the treatment of adult patients with transfusion-dependent anemia requiring transfusions associated with beta-thalassemia.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Before prescribing Reblozyl, please refer to the EU Summary of Product Characteristics.

References:

1. Reblozyl^® (luspatercept) Summary of Product Characteristics (SmPC). Celgene 2020.

2. Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor-b superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4):408-414.

3. Attie KM, Allison MJ, McClure T, et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Hematol. 2014;89(7):766-770.

This site is not intended for US or UK healthcare professionals.